Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

ual inpatient cost of heart failure.

About Nile Therapeutics
Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. The cenderitide program was granted Fast Track status by the United States Food and Drug Administration. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, Nile's belief about the viability of its strategy to develop cenderitide using a subcutaneous pump technology, Nile's plans for further development of cenderitide and its ability to fund such development, Nile's ability to obtain FDA approval of cenderitide in the post-acute setting and Nile's beliefs about the potential impact of a decrease of the ADHF re-hospitalization rate on the quality of life for patients and cenderitide's ability to reduce the financial burden of ADHF on the healthcare system, are forward-looking statements. Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Orexigen® Therapeutics Reports Third Quarter Financial Results
4. Silence Therapeutics Provides Corporate and Development Update
5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... for the 13th consecutive year at the Association ... Conference and Expo. The conference brings together professionals ... technologies. This year’s event will be held from ... The three-day event draws over 1,500 healthcare technology ...
(Date:5/21/2013)... NJ (PRWEB) May 21, 2013 Savoury ... industry, has appointed Dale Braddy to Southeastern USA Sales ... bolster its sales muscle in the Southeast. ... food ingredient brokerage and supplier to food processors and ... 13 years in the food industry and has over ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative entrance ... a Sanofi company and leading biotech company, recently ordered ... multi-use facility in the United States. With Door Detective ... latest order underscores the satisfaction and success the company ... improving doorway access control. , “We recommend Door ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... , ROCKVILLE, Md. , Feb. 5 Novavax, ... Dr. Rahul Singhvi , President and Chief Executive Officer of Novavax ... on February 8th, 2010 at 10:00 am local ... CEO & Investor Conference will take place February 8-9 at ...
... and a bit of high-grade plastic draws oil out of contaminated ... that oil absorbed can be squeezed back out for use. ... an aerogel, believe it will effectively clean up spills of all ... and oceans. , The EPA estimates that 10 to 25 million ...
... , DENVER , Feb. 4 ... leading employment communities for the hospitality and healthcare industries, are ... and job seekers. , (Photo: http://www.newscom.com/cgi-bin/prnh/20100204/FL49504LOGO-a ) , ... chosen Hcareers for the User,s Choice Award three times since ...
Cached Biology Technology:NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference 2New material absorbs, conserves oil 2Industry Web Sites Continue to Win Online Award 2Industry Web Sites Continue to Win Online Award 3
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/21/2013)... which alter the way genes function without changing ... in the blood of pregnant women during any ... depression in the weeks after giving birth, and ... , The findings of the small study involving ... journal Molecular Psychiatry . , "Postpartum depression ...
(Date:5/20/2013)... popularly known as the lungs of the planet, inhales carbon ... the air to grow parts that eventually fall to the ... plentiful rainfall. , Until recently people believed much of ... ended up deep in the ocean. University of Washington research ... carbon dioxide though left open the question of how ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... LA JOLLA, Calif., September 11, 2009 Dieter ... Medical Research (Burnham) have illuminated how competition between proteins ... proteins for destruction). Using S. pombe fission yeast as ... in which an array of Fbox proteins alternately attach ...
... Joseph,s Hospital and Medical Center has been awarded a $400,000 ... a rare cell type that is believed to play a ... this cell type have been seen in people suffering from ... A.D. "Bud" Craig, PhD, and other scientists in Barrow,s Atkinson ...
... types of fish we buy in stores or order in restaurants, ... higher than dying of natural causes. This may seem obvious to ... may not be apparent is that the relentless pursuit of consumer-friendly ... the world. By repeatedly choosing only the biggest fish, or only ...
Cached Biology News:When proteins change partners 2Changing the course of nature: Are fisheries directing the evolution of fish populations? 2
Verotoxin IIbeta (457)...
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Request Info...
Sterile, individually wrapped, 4mm Cuvettes...
Biology Products: